Abstract
Objective To investigate the expression of apoptosis inhibiting gene Survivin in breast cancer and the correlation of genes expression in cell cycle gene Cyclin D1 and multi-resistant gene p170. Methods To apply immunohistochemical methods and detect the gene expression of Survivin, Cyclin D1 and p170 in 72 cases of breast cancer and detect the gene expression of the other 16 cases in breast fibroadenoma and of 12 cases in normal tissue adjacent to carcinoma, at the same time to analyze the correlation between the two. Results the gene expression positive rate of Survivin, Cyclin D1 and p170 expression in breast cancer was 84.7% (61/72), 88.9% (64/72) and 93.1% (67/72) respectively. there are positive correlations between Survivin and Cyclin D1 and between Survivin and p170 (r=0.151, P=0.016; r=0.114, P=0.035); There is also a positive correlation relationship between Cyclin D1 and p170 (r=0.101, P=0.027), there are a low expression of Survivin gene 18.75% (3/16) in breast fibroadenoma and a zero expression of Survivin gene 0.00% (0/12) in normal tissue adjacent to breastcancer. Conclusion Survivin, Cyclin D1 and p170 genes may play a role of the tumor promotion through different ways, the three genes might participate in the progress of breast cancer in invasion, metastasis, recurrence and resistance, the collaborative detection of the above three genes will contribute to breast cancer prognosis judgement. Key words: Breast malignant tumor; Survivin; Cyclin D1; p170; Gene expression
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.